Cargando…

MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice

Obesity is often accompanied by hypertension. Although a large number of studies have confirmed that NLRP3 inhibitors can improve cardiac remodeling in mice with a normal diet, it is still unclear whether NLRP3 inhibitors can improve heart failure (HF) induced by pressure overload in obese mice. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Menglong, Zhao, Mengmeng, Yu, Junping, Xu, Yao, Zhang, Jishou, Liu, Jianfang, Zheng, Zihui, Ye, Jing, Wang, Zhen, Ye, Di, Feng, Yongqi, Xu, Shuwan, Pan, Wei, Wei, Cheng, Wan, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133382/ https://www.ncbi.nlm.nih.gov/pubmed/35647084 http://dx.doi.org/10.3389/fcvm.2022.727474

Ejemplares similares

The Role of Interleukin-6 Family Members in Cardiovascular Diseases
por: Feng, Yongqi, et al.
Publicado: (2022)

MCC950 closes the active conformation of NLRP3 to an inactive state
por: Tapia-Abellán, Ana, et al.
Publicado: (2019)

Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation
por: Xu, Liwei, et al.
Publicado: (2023)

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
por: Østergaard, Jakob A., et al.
Publicado: (2022)

Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice
por: Zhai, Yadong, et al.
Publicado: (2018)

The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Wang, Menglong, et al.
Publicado: (2023)

Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice
por: Ren, Pingping, et al.
Publicado: (2020)

MCC950, the NLRP3 Inhibitor, Protects against Cartilage Degradation in a Mouse Model of Osteoarthritis
por: Ni, Bowei, et al.
Publicado: (2021)

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages
por: Zeng, Wenyun, et al.
Publicado: (2021)

Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials
por: Grant, Angus J., et al.
Publicado: (2023)

Microglia‐Mediated Neuroimmune Response Regulates Cardiac Remodeling After Myocardial Infarction
por: Wang, Menglong, et al.
Publicado: (2023)

Inhibiting the NLRP3 Inflammasome With MCC950 Ameliorates Isoflurane-Induced Pyroptosis and Cognitive Impairment in Aged Mice
por: Fan, Yunxia, et al.
Publicado: (2018)

The Small Molecule NLRP3 Inflammasome Inhibitor MCC950 Does Not Alter Wound Healing in Obese Mice
por: Lee, James S., et al.
Publicado: (2018)

The Role of CXC Chemokines in Cardiovascular Diseases
por: Lu, Xiyi, et al.
Publicado: (2022)

A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target
por: Kennedy, Cassandra R., et al.
Publicado: (2021)

Il12a Deletion Aggravates Sepsis-Induced Cardiac Dysfunction by Regulating Macrophage Polarization
por: Wang, Zhen, et al.
Publicado: (2021)

MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure
por: Jiang, Xiaobo, et al.
Publicado: (2022)

A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation
por: Zhang, CongXiao, et al.
Publicado: (2019)

Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction
por: Zhang, Yi, et al.
Publicado: (2017)

IL-30 protects against sepsis-induced myocardial dysfunction by inhibiting pro-inflammatory macrophage polarization and pyroptosis
por: Zhao, Mengmeng, et al.
Publicado: (2023)

MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice
por: Perera, Agampodi Promoda, et al.
Publicado: (2018)

NLRP3 inflammasome inhibitor MCC950 can reduce the damage of pancreatic and intestinal barrier function in mice with acute pancreatitis
por: Shen, Yanghui, et al.
Publicado: (2022)

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Vande Walle, Lieselotte, et al.
Publicado: (2019)

The Selective NLRP3-inflammasome inhibitor MCC950 Mitigates Post-resuscitation Myocardial Dysfunction and Improves Survival in a Rat Model of Cardiac Arrest and Resuscitation
por: Zheng, Guanghui, et al.
Publicado: (2022)

IL-12p40 deletion aggravates lipopolysaccharide-induced cardiac dysfunction in mice
por: Liu, Menglin, et al.
Publicado: (2022)

Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy
por: Dubuisson, Nicolas, et al.
Publicado: (2022)

Intraperitoneal Injection of MCC950 Inhibits the Progression of Myopia in Form-Deprivation Myopic Mice
por: Chen, Zhengyu, et al.
Publicado: (2023)

MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury
por: Jiao, Jianhang, et al.
Publicado: (2020)

Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death
por: Matsuoka, Taisuke, et al.
Publicado: (2020)

NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway
por: Tang, Biao, et al.
Publicado: (2020)

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Walle, Lieselotte Vande, et al.
Publicado: (2019)

Blockage of KHSRP-NLRP3 by MCC950 Can Reverse the Effect of Manganese-Induced Neuroinflammation in N2a Cells and Rat Brain
por: Singh, Sharad, et al.
Publicado: (2022)

The Association between Obesity and Severity in Patients with Coronavirus Disease 2019: a Retrospective, Single-center Study, Wuhan
por: Zhang, Jishou, et al.
Publicado: (2021)

MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation
por: Jiang, Maorong, et al.
Publicado: (2020)

MCC950 Ameliorates Acute Liver Injury Through Modulating Macrophage Polarization and Myeloid-Derived Suppressor Cells Function
por: Yan, Wei, et al.
Publicado: (2021)

Interleukin-12p35 deficiency enhances mitochondrial dysfunction and aggravates cardiac remodeling in aging mice
por: Ye, Jing, et al.
Publicado: (2020)

Advances in the relationship between coronavirus infection and cardiovascular diseases
por: Zhao, Mengmeng, et al.
Publicado: (2020)

The Anti-inflammatory Mediator Resolvin E1 Protects Mice Against Lipopolysaccharide-Induced Heart Injury
por: Zhang, Jishou, et al.
Publicado: (2020)

Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress
por: Wang, Menglong, et al.
Publicado: (2022)

Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model
por: Sui, Ailing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_47m8d1sj559q0d8cimrngpsg71